For gastric cancer, the presence of various polymorphisms for genes coding IL-2, which is associated with poor prognosis in gastric cancer patients, might provide a therapeutic target to inhibit gastric cancer progression (Bai et al., 2014; Andersen et al., 2017). Here, IL2 is linked to gastric cancer.